Tumor Biology

, Volume 36, Issue 5, pp 3799–3806 | Cite as

Demethylation-mediated miR-129-5p up-regulation inhibits malignant phenotype of osteogenic osteosarcoma by targeting Homo sapiens valosin-containing protein (VCP)

  • Xin Hua Long
  • Yun Fei Zhou
  • Ai Fen Peng
  • Zhi Hong Zhang
  • Xuan Yin Chen
  • Wen Zhao Chen
  • Jia Ming Liu
  • Shan Hu Huang
  • Zhi Li Liu
Research Article


Previous studies demonstrated that increased Homo sapiens valosin-containing protein (VCP) may be involved in osteosarcoma (OS) metastasis. However, the underlying mechanism of VCP over-expression in OS remains unknown. In the present study, we found a significantly negative correlation between miR-129-5p and VCP protein expression in OS tissues with pulmonary metastasis (Spearman's rho, rs = −0.948). Bioinformatical prediction, Luciferase reporter assay, Western blot, and RT-PCR assays performed on OS cells indicated that VCP is a target of miR-129-5p. In addition, three CPG islands in the region of miR-129-5p promoter were detected by bioinformatical prediction, and significantly higher expression of miR-129-5p and lower methylation level of miR-129-2 gene in OS cells treated with 5-Aza-2′-deoxycytidine (a potent DNA demethylating agent) than in those untreated cells were observed. Furthermore, lower migratory and invasive ability was found in cells with elevated miR-129-5p than in those with decreased miR-129-5p. These findings indicated that increased miR-129-5p may be mediated by demethylation and inhibit OS cell migration and invasion by targeting VCP in OS, and targeting miR-129-5p/VCP signaling pathway may serve as a therapeutic strategy for OS management, although further studies will be necessary.


Demethylation miR-129-5p Osteosarcoma Malignant phenotype Valosin-containing protein 



The present study was supported by grants from the National Natural Science Foundation of China (No. 81360399) and the Natural Science Foundation of Jiangxi Province (No. 2012ZBAB205016).

Conflicts of interest



  1. 1.
    Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol. 2007;96:118–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Jawad MU, Cheung MC, Clarke J, Koniaris LG, Scully SP. Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol. 2011;137:597–607.CrossRefPubMedGoogle Scholar
  4. 4.
    Brand RA. 50 years ago in CORR: the present trend in treatment of osteogenic sarcoma. Clin Orthop Relat Res. 2009;467:3038–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013;5:591–616.CrossRefGoogle Scholar
  6. 6.
    Ogura T, Wilkinson AJ. AAA+ superfamily ATPases: common structure–diverse function. Genes Cells. 2001;6:575–97.CrossRefPubMedGoogle Scholar
  7. 7.
    Hetzer M, Meyer HH, Walther TC, Bilbao-Cortes D, Warren G, Mattaj IW. Distinct AAA-ATPase p97 complexes function in discrete steps of nuclear assembly. Nat Cell Biol. 2001;3:1086–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Nagano H, Dono K, et al. Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol. 2003;21:447–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Tsujimoto Y, Tomita Y, Hoshida Y, Kono T, Oka T, Yamamoto S, et al. Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res. 2004;10:3007–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Kidogami S, Miyata H, et al. Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma. Clin Cancer Res. 2004;10:5558–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, et al. Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol. 2003;21:2537–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Long XH, Zhang ZH, Liu ZL, Huang SH, Luo QF. Inhibiting valosin-containing protein suppresses osteosarcoma cell metastasis via AKT/nuclear factor of kappa B signaling pathway in vitro. Indian J Pathol Microbiol. 2013;56:190–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Liaw HH, Lin CC, Juan HF, Huang HC. Differential microRNA regulation correlates with alternative polyadenylation pattern between breast cancer and normal cells. PLoS One. 2013;8:e56958.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med. 2006;12:580–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia. 2013;15:180–91.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Doberstein K, Steinmeyer N, Hartmetz AK, Eberhardt W, Mittelbronn M, Harter PN, et al. MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia. 2013;15:218–30.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One. 2012;7:e35800.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kelly AD, Haibe-Kains B, Janeway KA, Hill KE, Howe E, Goldsmith J, et al. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 2013;5:2.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Asai T, Tomita Y, Nakatsuka S, Hoshida Y, Myoui A, Yoshikawa H, et al. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res. 2002;93:296–304.CrossRefPubMedGoogle Scholar
  20. 20.
    Yu X, Song H, Xia T, Han S, Xiao B, Luo L, et al. Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene. 2013;532:87–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res. 2013;32:96.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ma J, Hong L, Chen Z, Nie Y, Fan D. Epigenetic regulation of microRNAs in gastric cancer. Dig Dis Sci. 2014;59:716–23.CrossRefPubMedGoogle Scholar
  23. 23.
    Van den Hove DL, Kompotis K, Lardenoije R, Kenis G, Mill J, Steinbusch HW, et al. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol Aging. 2014;35:731–45.CrossRefPubMedGoogle Scholar
  24. 24.
    Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, et al. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. Neoplasia. 2013;15:511–22.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009;69:9038–46.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Shen R, Pan S, Qi S, Lin X, Cheng S. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394:1047–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Brest P, Lassalle S, Hofman V, Bordone O, Gavric Tanga V, Bonnetaud C, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18:711–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xin Hua Long
    • 1
  • Yun Fei Zhou
    • 1
  • Ai Fen Peng
    • 2
  • Zhi Hong Zhang
    • 1
  • Xuan Yin Chen
    • 1
  • Wen Zhao Chen
    • 1
  • Jia Ming Liu
    • 1
  • Shan Hu Huang
    • 1
  • Zhi Li Liu
    • 1
  1. 1.Department of OrthopedicsThe First Affiliated Hospital of Nanchang UniversityNanchangPeople’s Republic of China
  2. 2.Jiangxi University of Traditional Chinese MedicineNanchangPeople’s Republic of China

Personalised recommendations